{"id":603419,"date":"2022-06-08T19:00:02","date_gmt":"2022-06-08T19:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=603419"},"modified":"2022-06-08T19:00:02","modified_gmt":"2022-06-08T19:00:02","slug":"acanthamoeba-keratitis-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acanthamoeba-keratitis-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight_603419.html","title":{"rendered":"Acanthamoeba Keratitis Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1654675165.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acanthamoeba Keratitis Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1654675165.jpeg\" alt=\"Acanthamoeba Keratitis Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Acanthamoeba Keratitis Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Acanthamoeba Keratitis<\/strong> (AK) is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living ameba (a single-celled living organism) called Acanthamoeba. The organism causes AK when it infects the transparent outer covering of the eye called the cornea. The condition is very common in nature and can be found in water bodies (for example, lakes and oceans), soil, and air.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &#8220;<strong>Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032<\/strong>&#8221; report delivers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Acanthamoeba Keratitis Market<\/strong><\/a><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>As per a study conducted by Abelson et al. (2008), an estimated 5,000 cases of Acanthamoeba keratitis have occurred in the United States as of 2006, but since AK is so commonly misdiagnosed and the disease does not need to be reported to the Centers for Disease Control and Prevention, the actual number could be much higher. Approximately 88% of contact lens-related AK cases occur in soft contact lens wearers and 12% in rigid lens wearers.<\/li>\n<li>According to the studies it has been estimated that the disease affect male and female equally.<\/li>\n<li>According to Kozak et al. (2020), over 80% of Acanthamoeba keratitis appears in contact lens wearers. In one study, 75% of the patients were contact lens wearers; 40% wore daily soft lenses, 22% wore rigid gas permeable lenses, and 38% wore extended wear or other lenses.<\/li>\n<li>According to Booton et al. (2009), the genotype of 15 Acanthamoeba sp. isolates from AK cases from this outbreak using sequence analysis of a region of the 18S rDNA were determined. The results indicated that the isolates were predominantly genotype T4 (87%), with the remaining isolates being genotype T3 (13%). Both genotypes had previously been observed in AK cases.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acanthamoeba-keratitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/acanthamoeba-keratitis-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Acanthamoeba Keratitis Market<\/strong><\/a>&nbsp;<strong>Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Acanthamoeba Keratitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.<\/li>\n<li>Comprehensive insight has been provided into the Acanthamoeba Keratitis epidemiology and treatment in the 7MM.<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Acanthamoeba Keratitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/li>\n<li>A detailed review of the Acanthamoeba Keratitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acanthamoeba Keratitis market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Acanthamoeba Keratitis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Polihexanide (PHMB)<\/li>\n<li>And Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Acanthamoeba Keratitis Drugs<\/strong><\/a><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>SIFI<\/li>\n<li>And Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acanthamoeba-keratitis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/acanthamoeba-keratitis-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Acanthamoeba Keratitis<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Acanthamoeba Keratitis<\/p>\n<p style=\"text-align: justify;\">4. Acanthamoeba Keratitis: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Acanthamoeba Keratitis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Acanthamoeba Keratitis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Acanthamoeba Keratitis: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Acanthamoeba Keratitis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acanthamoeba-keratitis-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/acanthamoeba-keratitis-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acanthamoeba-keratitis-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acanthamoeba Keratitis Market Acanthamoeba Keratitis (AK) is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living ameba (a single-celled living organism) called Acanthamoeba. The &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acanthamoeba-keratitis-market-size-epidemiology-pipeline-therapies-companies-and-competitive-analysis-by-delveinsight_603419.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,404,416],"tags":[],"class_list":["post-603419","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/603419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=603419"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/603419\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=603419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=603419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=603419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}